Physician profile
Linh V Phan
NPI 1629485917
$5,277.43
in general payments reported to CMS, 2019-2025
17 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $142 · 2021: $375 · 2022: $625 · 2023: $682 · 2024: $1,913 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,610 · Entertainment: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,609.94 |
| Entertainment | $221.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,658.39 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $679.12 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $448.40 | 2022-2025 | |
| Dompe US, INC. | $357.41 | 2024 | Oxervate |
| Alcon Vision LLC | $329.06 | 2024-2025 | Total30, Precision7, Dailies Total1 |
| Harrow Eye, LLC | $222.18 | 2025 | Vevye |
| Optos, INC. | $221.24 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $213.45 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $200.51 | 2022-2024 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $161.60 | 2024 | Cirrus Hd-Oct |
| Apellis Pharmaceuticals, INC. | $146.17 | 2025 | |
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $128.69 | 2023 | Acuvue |
| Novartis Pharmaceuticals Corporation | $125.00 | 2020 | |
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $103.83 | 2024 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linh Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.